Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer without epidermal growth factor receptor mutations: A phase 2 trial.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2016 Last checked against the University Hospital Medical Information Network - Japan record.
- 10 Jun 2016 Status changed from recruiting to discontinued.
- 19 Apr 2013 New trial record